Sunday, May 14, 2023 3:45 PM – 5:45 PM ET Room 202A
Immune Checkpoint Blockade and CAR T/T Cell Therapy for Cancer Treatment
- Mark Rubenstein, Ohio State Univ.
- Michelle Krogsgaard, New York Univ. Sch. of Med.
- Benjamin C. Angeles, NCI, NIH, Generation of novel anti-tumor chimeric antigen receptors incorporating downstream T- cell signaling proteins
- Shubhabrata Majumdar, Univ. of Utah, CD3ζ ITAM diversity determines chimeric antigen receptor signaling and function
- Alfredo Amador, Mem. Sloan Kettering Cancer Ctr., CAR T-cell intrinsic PD1 Dominant Negative Receptor (PD1DNR) functions by both cell-intrinsic and extrinsic mechanisms
- Justin M. Mirazee, NCI, NIH, Hinging on success: leveraging the power of CAR T cell therapy through in-silico modeling of hinge length and epitope location
- Shannon Lynn Ferry, Geisel Sch. of Medicine, Dartmouth Col., Super2-IL-33 armored CAR T cells reshape the tumor microenvironment to universally suppress solid tumor growth
- Nathaniel Oberholtzer, Med. Univ. of South Carolina, Modulating the ER and Golgi stress response in T cells with hydrogen sulfide signaling to enhance the anti-tumor immune response
- Satomi Ando, Cincinnati Children's Hosp. Med. Ctr., mTOR signals regulate T cell exhaustion and T cell responses during PD-1 targeted immunotherapy in chronic viral infection
- Theodore Papadopoulos, Lady Davis Inst., Canada, Examining methotrexate's safety and efficacy in combination with immune checkpoint inhibitors to control immune related inflammatory arthritis in cancer